{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:00Z","timestamp":1787878200696,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.clinthera.2012.09.010","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T20:24:56Z","timestamp":1349987096000},"page":"2144-2160","source":"Crossref","is-referenced-by-count":91,"title":["Pharmacokinetic Properties of Mirabegron, a \u03b23-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00527033","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01285596","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01478503","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Walter","family":"Krauwinkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Schaddelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Eltink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Strabach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"van Marle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Kerbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"van Gelderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.09.010_bib1","first-page":"56","article-title":"The overactive bladder: an overview for primary care health providers","volume":"44","author":"Wein","year":"1999","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.clinthera.2012.09.010_bib2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0090-4295(03)00009-8","article-title":"Estimated economic costs of overactive bladder in the United States","volume":"61","author":"Hu","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2012.09.010_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2012.09.010_bib4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1464-410X.2006.05964.x","article-title":"Medical visits among adults with symptoms commonly associated with an overactive bladder","volume":"97","author":"Kim","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2012.09.010_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.clinthera.2012.09.010_bib6","doi-asserted-by":"crossref","first-page":"820816","DOI":"10.1155\/2011\/820816","article-title":"An overview of the clinical use of antimuscarinics in the treatment of overactive bladder","volume":"2011","author":"Athanasopoulos","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.clinthera.2012.09.010_bib9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b23-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2012.09.010_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/nau.20420","article-title":"\u03b23-adrenoceptors in urinary bladder","volume":"26","author":"Yamaguchi","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.clinthera.2012.09.010_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-9056(10)60758-0","article-title":"Dose-ranging study of once-daily mirabegron (YM178), a novel selective \u03b23-adrenoceptor agonist, in patients with overactive bladder (OAB)","volume":"9","author":"Chapple","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2012.09.010_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1569-9056(11)60870-1","article-title":"The efficacy and tolerability of mirabegron in patients with overactive bladder\u2014results from a European-Australian Phase III trial","volume":"10","author":"Khullar","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2012.09.010_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1569-9056(11)60869-5","article-title":"The efficacy and safety of mirabegron in patients with overactive bladder syndrome\u2014results from a North-American Phase III trial","volume":"10","author":"Nitti","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2012.09.010_bib16","first-page":"887","article-title":"Development and validation of LC-MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study","author":"van Teijlingen","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2012.09.010_bib17","series-title":"Clinical Pharmacokinetics: Concepts and Application","author":"Rowland","year":"1995"},{"key":"10.1016\/j.clinthera.2012.09.010_bib18","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications","author":"Gabrielsson","year":"2007"},{"key":"10.1016\/j.clinthera.2012.09.010_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":"Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Inf J"},{"key":"10.1016\/j.clinthera.2012.09.010_bib20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2012.09.010_bib25","series-title":"The International Encyclopedia of Pharmacology and Therapeutics","article-title":"Time-dependent pharmacokinetics","author":"Levy","year":"1982"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.09.010_bib26","first-page":"S88","article-title":"An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects","volume":"87","author":"Krauwinkel","year":"2010","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2012.09.010_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3109\/00498254.2012.675095","article-title":"Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.09.010_bib28","first-page":"S88","article-title":"An exploratory comparison of the single dose pharmacokinetics of the \u03b23-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers","volume":"85","author":"van Gelderen","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.09.010_bib29","doi-asserted-by":"crossref","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.09.010_bib30","unstructured":"Ushigome F, Takusagawa S, Li Q, et al. Mirabegron, a potent and selective \u03b23-adrenoceptor agonist, is a P-glycoprotein (P-gp) substrate: characterization of its efflux transport in Caco-2 and Human P-gp expressing cells and BCRP and MRP2 expressing vesicles. Drug Metab Rev. In press."},{"key":"10.1016\/j.clinthera.2012.09.010_bib31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.111.043588","article-title":"Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective \u03b23-adrenoceptor agonist, after oral administration to healthy male volunteers","volume":"40","author":"Takusagawa","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2012.09.010_bib32","doi-asserted-by":"crossref","unstructured":"Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Invest. In press.","DOI":"10.1007\/s40261-012-0031-3"},{"key":"10.1016\/j.clinthera.2012.09.010_bib33","series-title":"Cardiovascular Disease in the Elderly","first-page":"335","article-title":"Clinical pharmacology","author":"Schwartz","year":"2005"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812005322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812005322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T18:35:55Z","timestamp":1594751755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812005322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0149291812005322"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.09.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}